Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass., Nov. 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with one of multiple standard treatment regimens for patients with advanced solid tumors.
The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with these separate chemotherapy regimens. Study sites in North America and the European Union are expected to participate in this trial. The first patient was enrolled at Fox Chase Cancer Center in Philadelphia, PA.
Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.
Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, email@example.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, firstname.lastname@example.org
SOURCE Merrimack Pharmaceuticals, Inc.